Studies of the interactions of antibodies with their Fc receptors, with a particular focus on the neonatal Fc receptor (FcRn) and its relationship with IgG and albumin. In addition, we are investigating how FcRn acts as a transporter in different cell types of the body. The studies will unravel the basic structural and cellular mechanisms that govern the functions of FcRn. Such knowledge offers opportunities for development of novel drug concepts that will secure improved half-life and biodistribution.
Studies of the mechanisms of infections at different body sites and how humoral immunity fights and restricts infection and virus replication. In particular, we are studying how antibodies contribute to protection against infectious diseases, and how FcRn and tripartite motif containing 21 (TRIM21) take part in cellular protection. Such knowledge can be utilized to develop novel antibody technologies tailored to combat infectious diseases.
Recent publications
Nilsen J, Trabjerg E, Grevys A, Azevedo C, Brennan SO, Stensland M, Wilson J, Sand KMK, Bern M, Dalhus B, Roopenian DC, Sandlie I, Rand KD, Andersen JT(2020) An intact C-terminal end of albumin is required for its long half-life in humans Commun Biol, 3(1), 181 DOI 10.1038/s42003-020-0903-7, PubMed 32313072
Lode HE, Gjølberg TT, Foss S, Sivertsen MS, Brustugun J, Andersson Y, Jørstad ØK, Moe MC, Andersen JT(2019) A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes Sci Rep, 9(1), 18021 DOI 10.1038/s41598-019-54226-7, PubMed 31792234
Lau C, McAdam MB, Bergseth G, Grevys A, Bruun JA, Ludviksen JK, Fure H, Espevik T, Moen A, Andersen JT, Mollnes TE(2020) NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies MAbs, 12(1), 1686319 DOI 10.1080/19420862.2019.1686319, PubMed 31671278